- Home
- NCI vs CLRB Comparison
NCI vs CLRB Comparison
Compare NCI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCI
- CLRB
- Stock Information
- Founded
- NCI 1992
- CLRB 2002
- Country
- NCI Hong Kong
- CLRB United States
- Employees
- NCI N/A
- CLRB N/A
- Industry
- NCI
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- NCI
- CLRB Health Care
- Exchange
- NCI NYSE
- CLRB Nasdaq
- Market Cap
- NCI 10.1M
- CLRB 10.7M
- IPO Year
- NCI 2024
- CLRB N/A
- Fundamental
- Price
- NCI $0.53
- CLRB $0.31
- Analyst Decision
- NCI
- CLRB Buy
- Analyst Count
- NCI 0
- CLRB 2
- Target Price
- NCI N/A
- CLRB $28.00
- AVG Volume (30 Days)
- NCI 93.4K
- CLRB 4.5M
- Earning Date
- NCI 12-19-2024
- CLRB 11-18-2024
- Dividend Yield
- NCI N/A
- CLRB N/A
- EPS Growth
- NCI N/A
- CLRB N/A
- EPS
- NCI 0.08
- CLRB N/A
- Revenue
- NCI $22,481,862.00
- CLRB N/A
- Revenue This Year
- NCI N/A
- CLRB N/A
- Revenue Next Year
- NCI N/A
- CLRB N/A
- P/E Ratio
- NCI $7.39
- CLRB N/A
- Revenue Growth
- NCI N/A
- CLRB N/A
- 52 Week Low
- NCI $0.35
- CLRB $0.22
- 52 Week High
- NCI $11.39
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- NCI N/A
- CLRB 15.29
- Support Level
- NCI N/A
- CLRB $0.22
- Resistance Level
- NCI N/A
- CLRB $0.28
- Average True Range (ATR)
- NCI 0.00
- CLRB 0.05
- MACD
- NCI 0.00
- CLRB -0.01
- Stochastic Oscillator
- NCI 0.00
- CLRB 7.29
About NCI NEO-CONCEPT INTL GRP HLDGS LTD
Neo-Concept International Group Holdings Ltd is a company whose a one-stop apparel solution services provider. It offers a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management serving customers located in the European, and North American markets through Neo-Concept HK.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.